|Mr. Alexis A. Borisy||Co-Founder & Independent Chairman||55.62k||N/A||1972|
|Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A.||CEO, Pres & Director||987.19k||N/A||1974|
|Dr. Mark Murcko||Co-Founder & Director||181k||N/A||1960|
|Mr. Brian R. Adams J.D.||Gen. Counsel & Sec.||568.05k||N/A||1974|
|Dr. Donald A. Bergstrom||Exec. VP and Head of R&D||669.82k||N/A||1972|
|Mr. Thomas Catinazzo||Sr. VP of Fin.||N/A||N/A||1977|
|Mr. Peter Rahmer||Sr. VP of Corp. Affairs & Investor Relations||N/A||N/A||N/A|
|Dr. Deborah Palestrant Ph.D.||VP of Corp. Devel. & Strategy||N/A||N/A||N/A|
|Mr. Andy Porter||Exec. VP & Chief People Officer||N/A||N/A||N/A|
|Mr. Jim Watters Ph.D.||Sr. VP of Biology||N/A||N/A||N/A|
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 7; Compensation: 9.